End-of-day quote
Shanghai S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
36.7
CNY
|
+0.27%
|
|
+1.38%
|
-2.23%
|
Fiscal Period: December |
2019
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,665
|
8,906
|
12,099
|
11,829
|
-
|
-
|
Enterprise Value (EV)
1 |
5,665
|
8,906
|
12,099
|
11,829
|
11,829
|
11,829
|
P/E ratio
|
18.3
x
|
24.1
x
|
15.1
x
|
11.6
x
|
9.64
x
|
7.95
x
|
Yield
|
-
|
-
|
1.51%
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.51
x
|
-
|
3.86
x
|
3.44
x
|
2.91
x
|
2.45
x
|
EV / Revenue
|
4.51
x
|
-
|
3.86
x
|
3.44
x
|
2.91
x
|
2.45
x
|
EV / EBITDA
|
-
|
-
|
12.5
x
|
9.43
x
|
8.02
x
|
6.71
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
2.32
x
|
-
|
3.62
x
|
2.7
x
|
2.11
x
|
1.67
x
|
Nbr of stocks (in thousands)
|
322,319
|
322,319
|
322,319
|
322,319
|
-
|
-
|
Reference price
2 |
17.58
|
27.63
|
37.54
|
36.70
|
36.70
|
36.70
|
Announcement Date
|
3/12/20
|
3/10/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,256
|
-
|
3,134
|
3,438
|
4,070
|
4,828
|
EBITDA
1 |
-
|
-
|
968.2
|
1,255
|
1,475
|
1,762
|
EBIT
1 |
351.2
|
-
|
899.1
|
1,220
|
1,459
|
1,770
|
Operating Margin
|
27.96%
|
-
|
28.69%
|
35.49%
|
35.85%
|
36.66%
|
Earnings before Tax (EBT)
1 |
352.7
|
-
|
898.2
|
1,220
|
1,459
|
1,770
|
Net income
1 |
312.3
|
369.8
|
800.9
|
1,025
|
1,226
|
1,487
|
Net margin
|
24.87%
|
-
|
25.55%
|
29.81%
|
30.12%
|
30.8%
|
EPS
2 |
0.9615
|
1.146
|
2.485
|
3.177
|
3.808
|
4.615
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
0.5669
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/10/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
13.5%
|
-
|
25%
|
23.4%
|
21.9%
|
21%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
19.6%
|
19.2%
|
18.7%
|
Assets
1 |
-
|
-
|
-
|
5,230
|
6,385
|
7,952
|
Book Value Per Share
2 |
7.560
|
-
|
10.40
|
13.60
|
17.40
|
22.00
|
Cash Flow per Share
2 |
1.520
|
-
|
3.300
|
2.880
|
3.720
|
4.330
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/10/23
|
3/26/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -2.23% | 1.63B | | +26.08% | 681B | | +21.85% | 556B | | -4.77% | 361B | | +16.97% | 325B | | +5.69% | 285B | | +13.68% | 235B | | +3.65% | 199B | | -11.12% | 189B | | -3.40% | 157B |
Other Pharmaceuticals
|